-
-
-
-
-
-
-
AstraZeneca (AZN) Reports Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
-
-
-
-
-
-
-
Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
-
-
-
-
-
-
-
AstraZeneca (AZN) Announces FDA AdCom Recommends PT027 as Rescue Treatment for Asthma
-
-
-
-
-
-
-
Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial
-
-
-
-
-
-
-
AstraZeneca's (AZN) ENHERTU Granted Priority Review in the US for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
-
-
-
-
-
-
-
AstraZeneca's (AZN) Lynparza Granted Priority Review by the FDA
-
-
-
-
-
-
-
FibroGen (FGEN) to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week
-
12,341 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All